Zobrazeno 1 - 10
of 437
pro vyhledávání: '"Gérard, Zalcman"'
Autor:
Alexandre Brudon, Dorine Fournier, Frédéric Selle, Emmanuel Seront, Rosa Conforti, Gwenaëlle Veyrac, Aurore Gouraud, Bénédicte Lebrun-Vignes, Antoine Khalil, Gérard Zalcman, Valérie Gounant
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background PARP inhibitors (PARPi) are used in the treatment of ovarian, breast, pancreatic, and prostate cancers. Pneumonitis has been identified as a potential side effect, with a higher meta-analysis-assessed risk for olaparib versus othe
Externí odkaz:
https://doaj.org/article/50324750c659418484b2a66070fd6bcc
Autor:
Athéna Crespin, Clément Le Bescop, Jean de Gunzburg, Fabien Vitry, Gérard Zalcman, Julie Cervesi, Pierre-Alain Bandinelli
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) have considerably improved patient outcomes in various cancer types, but their efficacy remains poorly predictable among patients. The intestinal microbiome, whose balance and composition can be significa
Externí odkaz:
https://doaj.org/article/e43ddb3ef957401ebed60ef033e8f93e
Autor:
Julien Mazières, Diane Damotte, Virginie Westeel, Gérard Zalcman, Franck Morin, Marie-Ange Massiani, Jalal Assouad, Marie Wislez, Martine Antoine, Armelle Lavole, Olivier Carre, Thomas Egenod, Raffaele Caliandro, Catherine Dubos-Arvis, Gaelle Jeannin, Olivier Molinier, Alexandra Langlais, Francoise Le Pimpec Barthes, Laurent Brouchet, Bernard Milleron
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).Methods In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2,
Externí odkaz:
https://doaj.org/article/b39e97c95b144070ae7476897fa401e3
Autor:
Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I
Externí odkaz:
https://doaj.org/article/869532e7d9924a45b065a8c40a83cd05
Autor:
Clémentine Bouchez, Johan Pluvy, Ghassen Soussi, Marina Nguenang, Solenn Brosseau, Morgan Tourne, Mégane Collin, Nathalie Théou-Anton, Alice Guyard, Jamila Ammar, Antoine Khalil, Gérard Zalcman, Valérie Gounant
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Choroidal metastases are the most common eye metastatic site. The prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in historical series. Although previously reported, little is known ab
Externí odkaz:
https://doaj.org/article/1268407c0f254ad3a46c9bc97e72332e
Autor:
Emilie Lissavalid, Antoine Khalil, Ghassen Soussi, Marie-Pierre Debray, Alice Guyard, Vincent Bunel, Raphael Borie, Pierre Mordant, Aurélie Cazes, Gérard Zalcman, Valérie Gounant
Publikováno v:
ERJ Open Research, Vol 8, Iss 1 (2022)
Background Computed tomography (CT) screening has improved lung cancer survival, yet increasingly detects small lung lesions. Thus, the number of transthoracic lung biopsies (TTLB) for small nodules is expected to rise significantly. The aim of the p
Externí odkaz:
https://doaj.org/article/08f4449e2ae84361ae7892819b3ee532
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis invol
Externí odkaz:
https://doaj.org/article/e91a07b7af214347969f6468847e92a5
Autor:
Pierre-Alain Bandinelli, Julie Cervesi, Clément Le Bescop, Renaud Buffet, Jean De Gunzburg, Gérard Zalcman, Athéna Crespin, Fabien Vitry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f038b988af4e4f2aa6a84d70788e368b
Autor:
Capucine Baldini, Francois-Xavier Danlos, Aurélien Marabelle, Jean-Charles Soria, Christophe Massard, Lydie Cassard, Julien Adam, David Planchard, Andreea Varga, Gérard Zalcman, Nathalie Chaput-Gras, Matthieu Texier, Severine Mouraud, Bastien Job, Diane Letourneur, Delphine Bredel, Salim Laghouati, Nathalie Droin, Aurelien Parpaleix, Audrey Rabeau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/88c4a66df07f4921b9789c2c5c470244
Autor:
Raphael Borie, Benoit Funalot, Ralph Epaud, Céline Delestrain, Aurélie Cazes, Valerie Gounant, Justine Frija, Marie-Pierre Debray, Gérard Zalcman, Bruno Crestani
Publikováno v:
ERJ Open Research, Vol 7, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/ea4fc884a878498586bfee33552515b1